NASDAQ$SGHT
Sight Sciences Inc · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Headline financials
Revenue & EPS history
Sight Sciences · Revenue · Quarterly
$3.5M
Q2 2020
Revenue by segment
Sight Sciences · $3.48M total across 2 segments · Q2 2020
- Interventional Glaucoma$3.29M—94.6%
- Interventional Dry Eye$186K—5.4%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports
+3.0%
Avg return
Earnings day
+4.0%
Avg return
5 days after
+5.0%
Avg return
30 days after
53%
10 / 19 earnings
Positive
+60.9%
Q3 2022
Best reaction
-26.9%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.7% | +22.6% | +2.5% | |
| Q4 2025 | -26.9% | -25.9% | -34.9% | |
| Q3 2025 | +16.0% | +54.4% | +61.0% | |
| Q1 2025 | +1.3% | +8.3% | +38.6% | |
| Q4 2024 | +2.9% | +15.3% | -5.0% | |
| Q3 2024 | -17.1% | -17.1% | -24.1% | |
| Q2 2024 | -18.9% | -29.4% | -13.0% | |
| Q1 2024 | +6.6% | +1.1% | +17.4% | |
| Q4 2023 | +6.8% | -4.4% | +21.4% | |
| Q3 2023 | +19.8% | +2.0% | +54.1% | |
| Q2 2023 | +11.0% | +4.1% | -16.0% | |
| Q1 2023 | -0.4% | +0.6% | -25.1% | |
| Q4 2022 | +4.9% | -2.3% | -5.8% | |
| Q3 2022 | +60.9% | +50.4% | +72.9% | |
| Q2 2022 | -3.9% | -16.1% | -26.2% | |
| Q1 2022 | +11.2% | +23.9% | +59.2% | |
| Q4 2021 | -10.1% | -6.1% | -45.5% | |
| Q3 2021 | -2.4% | -5.8% | -20.6% | |
| Q2 2021 | -4.7% | +0.1% | -15.9% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro